|
|
 |
|
Viewing report
|
|
|
|
Neurodegenerative Drugs - Global Strategic Business Report
Global Industry Analysts, Inc., April 2010, Pages: 1,108
This report analyzes the worldwide markets for Neurodegenerative Drugs in US$ Million by the following disease types: Alzheimers Disease, Parkinsons Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Other Neurodegenerative Diseases.
The report provides separate comprehensive analytics for the US, Europe, and Rest of World.
Annual estimates and forecasts are provided for each region for the period 2006 through 2015.
The report profiles 165 companies including many key and niche players such as Amarin Corporation PLC, AstraZeneca PLC, Avanir Pharmaceuticals, Inc., Avigen, Inc., Bayer Schering Pharma AG, Boehringer Ingelheim GmbH, Biogen Idec Inc., Bristol-Myers Squibb Co., Biovail Corporation, Ceregene, Inc., Eisai, Inc., Elan Pharmaceuticals, Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline PLC, H. Lundbeck A/S, Merz Pharmaceuticals GMBH, Merck Serono SA, Mitsubishi Tanabe Pharma Corporation, Neurologix, Inc., NeuroSearch A/S, Novartis AG, Pfizer, Inc., Sanofi-aventis S.A, Shire Pharmaceuticals Group PLC, Teva Pharmaceutical Industries Limited, Valeant Pharmaceuticals International, and Wyeth Pharmaceuticals, Inc.
Market data and analytics are derived from primary and secondary research.
Company profiles are mostly extracted from URL research and reported select online sources.
Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.
For information on site licence pricing please click on Enquire before buying
Customers who bought this item also bought
Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth
Neurodegenerative Market Forecast to 2013
Endpoints - Clinical Trials in CNS Disorders - Multiple Endpoints and Ratings Scales are Becoming More Widely Adopted
CNS Therapeutics - Global Strategic Business Report
Lou Gehrigs Disease - Global Strategic Business Report
Clinical Trial Recruitment in Orphan Diseases - Patient Numbers in Ovarian Cancer Trials Exceed Other Orphan Diseases in Oncology
Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies
Amyotrophic Lateral Sclerosis - Orphan Status, Unmet Need, and Diverse Drug Targets Offer Opportunities for Drug Developers
Amyotrophic Lateral Sclerosis (ALS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Multiple Sclerosis Therapeutics - Global Strategic Business Report
|
|
|
|
